Investors Purchase Large Volume of Maravai LifeSciences Put Options (NASDAQ:MRVI)

Key Points

• Unusual put activity: Traders purchased 1,002 put options on MRVI — roughly a 1,791% increase versus the typical 53 puts — indicating elevated bearish bets or hedging activity.
• Institutional investors have been active, with T. Rowe Price holding about 6.34 million shares and Wellington initiating a roughly $7.7M position; institutions now own roughly 50.25% of the company.
• MRVI trades near $3.50 with a market cap around $900M; the company posted a slight EPS beat (-$0.04 vs. -$0.07) and $49.87M revenue but still has negative margins, and analysts' consensus is a "Hold" with a $5.38 target.

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Get Free Report) was the target of some unusual options trading on Wednesday. Stock traders purchased 1,002 put options on the company. This represents an increase of approximately 1,791% compared to the typical volume of 53 put options.

Institutional Investors Weigh In On Maravai LifeSciences

A number of institutional investors and hedge funds have recently modified their holdings of MRVI. Virtu Financial LLC purchased a new stake in shares of Maravai LifeSciences in the fourth quarter worth $34,000. T. Rowe Price Investment Management Inc. raised its position in Maravai LifeSciences by 2.9% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 6,336,680 shares of the company's stock valued at $20,595,000 after purchasing an additional 178,445 shares in the last quarter. Invesco Ltd. raised its stake in shares of Maravai LifeSciences by 12.3% during the fourth quarter. Invesco Ltd. now owns 345,773 shares of the company's stock worth $1,124,000 after acquiring an additional 37,958 shares in the last quarter. Mackenzie Financial Corp raised its stake in shares of Maravai LifeSciences by 1.7% during the fourth quarter. Mackenzie Financial Corp now owns 6,173,656 shares of the company's stock worth $20,148,000 after acquiring an additional 104,355 shares in the last quarter. Finally, Wellington Management Group LLP purchased a new position in shares of Maravai LifeSciences in the fourth quarter worth about $7,670,000. 50.25% of the stock is owned by hedge funds and other institutional investors.

Maravai LifeSciences Price Performance

Maravai LifeSciences stock opened at $3.50 on Thursday. The company has a market cap of $899.75 million, a price-to-earnings ratio of -3.89 and a beta of 0.43. Maravai LifeSciences has a 12 month low of $1.66 and a 12 month high of $4.11. The company has a current ratio of 6.60, a quick ratio of 5.69 and a debt-to-equity ratio of 0.85. The business's 50 day simple moving average is $3.17 and its 200 day simple moving average is $3.35.

Maravai LifeSciences (NASDAQ:MRVI - Get Free Report) last released its quarterly earnings data on Wednesday, February 25th. The company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.07) by $0.03. The business had revenue of $49.87 million for the quarter, compared to the consensus estimate of $49.06 million. Maravai LifeSciences had a negative net margin of 70.40% and a negative return on equity of 22.79%. Sell-side analysts forecast that Maravai LifeSciences will post -0.24 EPS for the current year.

Analysts Set New Price Targets

Separately, Wall Street Zen raised shares of Maravai LifeSciences from a "sell" rating to a "hold" rating in a report on Saturday, February 28th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $5.38.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc NASDAQ: MRVI is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company's offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai's platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.